



Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner called to indicate that claims that were amended to be limited in scope to nucleic acids encoding an enzyme comprising a polypeptide with at least 95% identity to SEQ ID NO:2; wherein the polypeptide catalyzes transfer of galacturonosyl residues to an oligomer of galacturonic acid residues would be fully enabled, described, and free of the prior art of record. If the product claims are amended to this scope, then process claims that depend from or otherwise include the same limitations will be rejoined. Claims directed to an isolated polypeptide will not be rejoined, because that is subject matter that is examined in a different art unit. The Examiner hoped to negotiate Examiner's amendments to be able to allow the case. Unfortunately, Donna Ferber informed the Examiner that the Applicant has indicated they wish to transfer the case to a different attorney, and therefore, she was not able to approve any Examiner's amendments..